ramucirumab
ramucirumab: developed by 1 company · 31 clinical trials tracked · 1 FDA decision.
ramucirumab evidence translation
What we can confirm
1 FDA record · 31 tracked trials
What it means
What to watch
Prepared research question
How could ramucirumab → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 8 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| ELI LILLY & Co (LLY) Neoplasms; Desmoplastic Small Round Cell Tumor; Biliary Trac… | Phase 3 |
| ELI LILLY & Co (LLY) For use as monotherapy or in combination with another agent … | Approved |
Clinical Trials (31)showing 10 most recent
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Primary endpoint: Objective Response Rate (ORR)
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Primary endpoint: Part A and Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
Primary endpoint: Number of participants with adverse events (AE) and serious adverse events (SAE)
A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Primary endpoint: Overall survival (OS)
Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Solid Tumors
Primary endpoint: Number/incidence and percentage of subjects with adverse events.
A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)
Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D
Primary endpoint: Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Primary endpoint: Progression free survival (PFS) (Phase II)
A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Primary endpoint: Progression-free survival
Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)
Primary endpoint: Objective Response Rate (ORR)
FDA Decisions1 records
Frequently asked questions
Who is developing ramucirumab?
ramucirumab is being developed by ELI LILLY & Co.
How many clinical trials involve ramucirumab?
BioSniper tracks 31 clinical trials involving ramucirumab.
What is ramucirumab's latest FDA decision?
The most recent tracked FDA decision for ramucirumab is Approval, dated April 21, 2014.